Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Consensus Price Target of $20.72 According to Brokerages

Posted by George Bondi on Oct 24th, 2026

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received a consensus rating of “Hold” from the twenty-three analysts that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $20.72.

NTLA has been the subject of several recent analyst reports. Wedbush increased their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Wolfe Research downgraded shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a report on Wednesday, July 15th. Citizens Jmp reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Barclays assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th.

Get Our Latest Research Report on NTLA

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.21 on Friday. The stock has a 50 day moving average price of $12.22 and a 200 day moving average price of $13.12. The stock has a market capitalization of $1.57 billion, a PE ratio of -3.34 and a beta of 1.80. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $26.35.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. During the same quarter in the previous year, the firm earned ($0.98) EPS. The business’s quarterly revenue was down 46.4% on a year-over-year basis. As a group, research analysts forecast that Intellia Therapeutics will post -3.21 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NTLA. PNC Financial Services Group Inc. lifted its stake in shares of Intellia Therapeutics by 36.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after buying an additional 948 shares during the last quarter. Wealthfront Advisers LLC grew its stake in Intellia Therapeutics by 7.6% in the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after buying an additional 1,018 shares during the last quarter. Wellington Management Group LLP grew its stake in Intellia Therapeutics by 2.7% in the 2nd quarter. Wellington Management Group LLP now owns 43,484 shares of the company’s stock valued at $736,000 after buying an additional 1,125 shares during the last quarter. Axxcess Wealth Management LLC grew its stake in Intellia Therapeutics by 6.1% in the 1st quarter. Axxcess Wealth Management LLC now owns 22,707 shares of the company’s stock valued at $291,000 after buying an additional 1,308 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC raised its holdings in Intellia Therapeutics by 6.1% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 26,986 shares of the company’s stock valued at $325,000 after acquiring an additional 1,556 shares during the period. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.